Published in J Hypertens on April 01, 2006
The pathogenesis of cardiac fibrosis. Cell Mol Life Sci (2013) 1.96
Fibroblasts in myocardial infarction: a role in inflammation and repair. J Mol Cell Cardiol (2013) 1.61
Fibroblasts in post-infarction inflammation and cardiac repair. Biochim Biophys Acta (2012) 1.41
Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells. Kidney Int (2010) 1.12
Busulfan-induced senescence is dependent on ROS production upstream of the MAPK pathway. Free Radic Biol Med (2007) 0.97
Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Exp Mol Med (2009) 0.92
Angiotensin II-induced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium. Exp Eye Res (2009) 0.85
Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II. Am J Physiol Cell Physiol (2008) 0.83
A metabolite of Danshen formulae attenuates cardiac fibrosis induced by isoprenaline, via a NOX2/ROS/p38 pathway. Br J Pharmacol (2015) 0.80
A cell culture model using rat coronary artery adventitial fibroblasts to measure collagen production. BMC Cardiovasc Disord (2007) 0.80
PEP-1-SOD1 fusion proteins block cardiac myofibroblast activation and angiotensin II-induced collagen production. BMC Cardiovasc Disord (2015) 0.78
Cardiac melanocytes influence atrial reactive oxygen species involved with electrical and structural remodeling in mice. Physiol Rep (2015) 0.78
Phos-tag SDS-PAGE resolves agonist- and isoform-specific activation patterns for PKD2 and PKD3 in cardiomyocytes and cardiac fibroblasts. J Mol Cell Cardiol (2016) 0.76
Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps. Trends Pharmacol Sci (2017) 0.75
Oxidative Stress and Hypertensive Diseases. Med Clin North Am (2016) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
American College of Sports Medicine position stand. Exercise and hypertension. Med Sci Sports Exerc (2004) 4.48
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med (2002) 3.61
Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. JAMA (2004) 3.33
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens (2010) 2.49
J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med (2002) 2.45
Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J (2009) 2.37
High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. Eur Heart J (2003) 2.05
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension (2012) 2.02
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens (2004) 1.87
Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. J Hypertens (2003) 1.78
Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone. Hypertension (2009) 1.69
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial - HYVET. J Hypertens (2013) 1.53
Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens (2006) 1.53
Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery. J Hypertens (2002) 1.48
Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes (2010) 1.48
Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol (2007) 1.44
Carotid and femoral intima-media thickness in relation to three candidate genes in a Caucasian population. J Hypertens (2002) 1.44
Abnormal regulation of G protein alpha(i2) subunit in skin fibroblasts from insulin-resistant hypertensive individuals. J Hypertens (2004) 1.42
Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens (2014) 1.41
Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension (2005) 1.41
Relationship between left ventricular mass and the ACE D/I polymorphism varies according to sodium intake. J Hypertens (2004) 1.40
Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke (2006) 1.33
Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol (2006) 1.30
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol (2012) 1.28
Upregulation of Na+ and Ca2+ transporters in arterial smooth muscle from ouabain-induced hypertensive rats. Am J Physiol Heart Circ Physiol (2009) 1.24
Association between arterial properties and renal sodium handling in a general population. Hypertension (2006) 1.24
Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens (2006) 1.20
Birth weight and body composition in young women: a prospective twin study. Am J Clin Nutr (2002) 1.19
Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. Arch Intern Med (2011) 1.14
Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis (2007) 1.12
Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes (2005) 1.05
In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care (2010) 1.04
Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens (2010) 1.02
Salt, endogenous ouabain and blood pressure interactions in the general population. J Hypertens (2003) 1.01
Determinants of the effects of physical training and of the complications requiring resuscitation during exercise in patients with cardiovascular disease. Eur J Cardiovasc Prev Rehabil (2004) 1.00
Callipeltin A: sodium ionophore effect and tension development in vascular smooth muscle. Biochem Pharmacol (2004) 0.99
CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens (2009) 0.99
Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta Cardiol (2003) 0.98
Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens (2007) 0.96
Association between hypertension and variation in the alpha- and beta-adducin genes in a white population. Kidney Int (2002) 0.93
Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation (2004) 0.92
Depression and the heart: a systematic overview of definition, measurement, consequences and treatment of depression in cardiovascular disease. Eur J Cardiovasc Nurs (2002) 0.92
Cardiovascular and biochemical risk factors for incident dementia in the Hypertension in the Very Elderly Trial. J Hypertens (2009) 0.92
Heritability and intrafamilial aggregation of arterial characteristics. J Hypertens (2008) 0.91
A genetic predisposition score for muscular endophenotypes predicts the increase in aerobic power after training: the CAREGENE study. BMC Genet (2011) 0.91
Terminal digit preference and single-number preference in the Syst-Eur trial: influence of quality control. Blood Press Monit (2002) 0.91
Host and environmental determinants of polychlorinated aromatic hydrocarbons in serum of adolescents. Environ Health Perspect (2002) 0.90
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol (2007) 0.90
Effect of exercise training in patients with an implantable cardioverter defibrillator. Eur Heart J (2004) 0.90
Vitamin C prevents zidovudine-induced NAD(P)H oxidase activation and hypertension in the rat. Cardiovasc Res (2006) 0.90
Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. Am J Hypertens (2004) 0.89
Transforming growth factor-beta 1-mediated collagen gel contraction by cardiac fibroblasts. J Renin Angiotensin Aldosterone Syst (2003) 0.89
Blood pressure in relation to three candidate genes in a Chinese population. J Hypertens (2004) 0.89
Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab (2004) 0.89
An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats. Hepatology (2008) 0.88
Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3'-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes (2004) 0.88
Short-term and long-term repeatability of the morning blood pressure in older patients with isolated systolic hypertension. J Hypertens (2008) 0.88
G-protein beta3-subunit gene 825T allele and hypertension: a longitudinal study in young grade I hypertensives. Hypertension (2003) 0.87
Influenza vaccination and major adverse vascular events in high-risk patients. Circulation (2012) 0.86
Inhibition of superoxide dismutase induces collagen production in cardiac fibroblasts. Am J Hypertens (2008) 0.86
Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CMAJ (2012) 0.86
Genetic and environmental influences on blood pressure variability: a study in twins. J Hypertens (2013) 0.86